Solid-tumor biomarker
Gastric Carcinoma GC-REAAD
An investigational-style diagnostic offering associated with gastric carcinoma on the former site.
Product overview
What it is.
- Restalyst GC-REAAD™ ITIH3 ELISA: an in-vitro diagnostic for the qualitative and semi-quantitative detection of ITIH3 protein in human plasma, intended for early detection of gastric carcinoma.
- Built on a patented technology; ITIH3 is reported to be elevated in the plasma of gastric-carcinoma patients regardless of gastritis status or H. pylori infection.
- Reports a positive or negative risk result using an arbitrary measurement scale called REAAD-units (RU).
How it works
A sandwich ELISA. Capture antibodies coated on the microwell bind ITIH3 in the plasma sample; detection antibodies and HRP-conjugated secondary antibodies are added, and a TMB substrate turns into a colour signal whose intensity is proportional to the antigen present. Wells are read on any suitable spectrophotometer or ELISA reader.
Specifications
Key figures.
- Sensitivity
- 91.0%
- Specificity
- 93.6%
- Inter-assay precision
- 7.59% – 8.64%
- Intra-assay precision
- 3.32% – 3.74%
- Sample type
- Plasma
- Assay duration (approx.)
- 2 hours
- Patient sample volume
- <10 µL
- Shelf life
- 12 months
- Certification
- CE-IVD certified; HSA (Singapore) registered
Portfolio information
From the original portfolio.
The legacy description identifies an ITIH3 ELISA assay for human plasma. Current availability, validation, and intended use require confirmation.
This page preserves the former site’s product information for review. It does not establish current Canadian availability, approved indications, performance, or prescribing information. Request verified documentation before relying on it.
Request verified informationExplore this area